The Hsa-Mir-3613–5P, a Potential Oncogene Correlated With Diagnostic and Prognostic Merits in Kidney Renal Clear Cell Carcinoma Publisher Pubmed



Ahmadi M¹ ; Najarihanjani P² ; Ghaffarnia R³ ; Ghaderian SMH¹ ; Mousavi P⁴ ; Ghafourifard S¹ Show Affiliations
Source: Pathology Research and Practice Published:2023

Abstract

MicroRNA-3613 (hsa-miR-3613–5p), a biomarker with a dual role as an oncogenic or tumor suppressor, is associated with different types of cancer. This study aimed to determine the correlation between the hsa-miR-3613–5p gene expression and Kidney renal clear cell carcinoma (KIRC). Utilizing several bioinformatics tools, we examined the expression level and clinicopathological value of hsa-miR-3613–5p in patients with KIRC compared to normal tissues. Other bioinformatic measures, including survival analysis, diagnostic merit of hsa-miR-3613–5p, downstream target prediction, potential upstream lncRNAs, network construction, and functional enrichment analysis of hsa-miR-3613–5p, were performed. We observed that overexpression of hsa-miR-3613–5p in KIRC tissues had valuable diagnostic merit and was significantly correlated with the poor overall survival of KIRC patients. We also realized a correlation between abnormal expression of hsa-miR-3613–5p and several clinical parameters such as pathological stage, race, age, and histological grades in patients with KIRC. Moreover, we constructed the most potential regulatory network of hsa-miR-3613–5p in KIRC with 17 different axes, including four pseudogenes, two lncRNAs, and three mRNAs. Besides, we uncovered six variants in the mature form of hsa-miR-3613–5p. Finally, pathway enrichment analysis demonstrated that the top-ranked pathways for hsa-miR-3613–5p are cell cycle, cell adhesion molecules (CAMs), and hepatocellular carcinoma pathways. The present report suggests that the higher expression of hsa-miR-3613–5p is associated with the progression of KIRC. Therefore, it may be considered a valuable indicator for the early detection, risk stratification, and targeted treatment of patients with KIRC. © 2023